REPORTS

Let’s Pullulate and Expand Your Business

Neisseria Gonorrhoeae Infections Treatment Market - Global Professional Analysis and Forecast to 2026

Jan 26, 2020  |  156 PAGES  |  REPORT CODE: CMM263536
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Neisseria Gonorrhoeae Infections Treatment market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.9% during the forecast period.

This report presents the market size and development trends by detailing the Neisseria Gonorrhoeae Infections Treatment market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neisseria Gonorrhoeae Infections Treatment market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neisseria Gonorrhoeae Infections Treatment industry and will help you to build a panoramic view of the industrial development.

Neisseria Gonorrhoeae Infections Treatment Market, By Type:

  • Cribrostatin-6

  • Dalbavancin

  • Debio-1453

  • Gepotidacin Mesylate

  • Others

Neisseria Gonorrhoeae Infections Treatment Market, By Application:

  • Clinic

  • Hospital

  • Others

Some of the leading players are as follows:

  • Merck & Co., Inc.

  • GlaxoSmithKline Plc

  • Sarepta Therapeutics, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Redx Pharma Plc

  • BioDiem Ltd

  • Recce Pty Ltd

  • Debiopharm International SA

  • Sumitomo Dainippon Pharma Co., Ltd.

  • Paratek Pharmaceuticals, Inc.

  • Biolytics Pharma

  • Allergan Plc

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Neisseria Gonorrhoeae Infections Treatment Market: Technology Type Analysis

  • 4.1 Neisseria Gonorrhoeae Infections Treatment Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Neisseria Gonorrhoeae Infections Treatment Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Cribrostatin-6

    • 4.3.2 Dalbavancin

    • 4.3.3 Debio-1453

    • 4.3.4 Gepotidacin Mesylate

    • 4.3.5 Others

5 Neisseria Gonorrhoeae Infections Treatment Market: Product Analysis

  • 5.1 Neisseria Gonorrhoeae Infections Treatment Product Market Share Analysis, 2018 & 2026

  • 5.2 Neisseria Gonorrhoeae Infections Treatment Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Neisseria Gonorrhoeae Infections Treatment Market: Application Analysis

  • 6.1 Neisseria Gonorrhoeae Infections Treatment Application Market Share Analysis, 2018 & 2026

  • 6.2 Neisseria Gonorrhoeae Infections Treatment Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Clinic

    • 6.3.2 Hospital

    • 6.3.3 Others

7 Neisseria Gonorrhoeae Infections Treatment Market: Regional Analysis

  • 7.1 Neisseria Gonorrhoeae Infections Treatment Regional Market Share Analysis, 2018 & 2026

  • 7.2 Neisseria Gonorrhoeae Infections Treatment Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Merck & Co., Inc.

    • 9.1.1 Merck & Co., Inc. Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 GlaxoSmithKline Plc

    • 9.2.1 GlaxoSmithKline Plc Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Sarepta Therapeutics, Inc.

    • 9.3.1 Sarepta Therapeutics, Inc. Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 F. Hoffmann-La Roche Ltd.

    • 9.4.1 F. Hoffmann-La Roche Ltd. Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Redx Pharma Plc

    • 9.5.1 Redx Pharma Plc Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 BioDiem Ltd

    • 9.6.1 BioDiem Ltd Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Recce Pty Ltd

    • 9.7.1 Recce Pty Ltd Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Debiopharm International SA

    • 9.8.1 Debiopharm International SA Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Sumitomo Dainippon Pharma Co., Ltd.

    • 9.9.1 Sumitomo Dainippon Pharma Co., Ltd. Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Paratek Pharmaceuticals, Inc.

    • 9.10.1 Paratek Pharmaceuticals, Inc. Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Biolytics Pharma

    • 9.11.1 Biolytics Pharma Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Allergan Plc

    • 9.12.1 Allergan Plc Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

 

The List of Tables and Figures (Totals 95 Figures and 126 Tables)

  • Figure Cribrostatin-6 Neisseria Gonorrhoeae Infections Treatment market, 2015 - 2026 (USD Million)

  • Figure Dalbavancin Neisseria Gonorrhoeae Infections Treatment market, 2015 - 2026 (USD Million)

  • Figure Debio-1453 Neisseria Gonorrhoeae Infections Treatment market, 2015 - 2026 (USD Million)

  • Figure Gepotidacin Mesylate Neisseria Gonorrhoeae Infections Treatment market, 2015 - 2026 (USD Million)

  • Figure Others Neisseria Gonorrhoeae Infections Treatment market, 2015 - 2026 (USD Million)

  • Figure Clinic market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Neisseria Gonorrhoeae Infections Treatment market, by country, 2015 - 2026 (USD Million)

  • Table North America Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table North America Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table North America Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Canada Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Canada Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Europe Neisseria Gonorrhoeae Infections Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Europe Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Europe Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Europe Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Germany Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Germany Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table France Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table France Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Italy Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Italy Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Spain Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Spain Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria Gonorrhoeae Infections Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table China Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table China Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Japan Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Japan Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table India Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table India Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria Gonorrhoeae Infections Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table MEA Neisseria Gonorrhoeae Infections Treatment market, by country, 2015 - 2026 (USD Million)

  • Table MEA Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table MEA Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table MEA Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Neisseria Gonorrhoeae Infections Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Neisseria Gonorrhoeae Infections Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Neisseria Gonorrhoeae Infections Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Merck & Co., Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sarepta Therapeutics, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table F. Hoffmann-La Roche Ltd. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Redx Pharma Plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BioDiem Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Recce Pty Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Debiopharm International SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sumitomo Dainippon Pharma Co., Ltd. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Paratek Pharmaceuticals, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biolytics Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan Plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top